Hawaii 2023 Regular Session

Hawaii Senate Bill SCR133 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.C.R. NO. 133 THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII SENATE CONCURRENT RESOLUTION requesting the department of health to convene a therapeutic psilocybin working group.
2	2
3	3	THE SENATE S.C.R. NO. 133
4	4	THIRTY-SECOND LEGISLATURE, 2023
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.C.R. NO.
10	10
11	11	133
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2023
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29	SENATE CONCURRENT
30	30
31	31	RESOLUTION
32	32
33	33
34	34
35	35
36	36
37	37	requesting the department of health to convene a therapeutic psilocybin working group.
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45	WHEREAS, there is heightened awareness of the detrimental effects of untreated and maltreated mental health in the State's population; and WHEREAS, with a shortage of mental health professionals and appropriate mental health care, the State must actively consider innovative and effective treatment options to address this pressing need; and WHEREAS, psilocybin has been found to be very effective in treating a variety of mental health conditions, including but not limited to post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress; and WHEREAS, the United States Food and Drug Administration has designated treatment that uses psilocybin in a therapeutic manner for treatment-resistant depression as a "breakthrough therapy"; and WHEREAS, at least two states, Colorado and Oregon, have found that legalizing medicinal psilocybin is a valuable tool in dealing with various mental health conditions; and WHEREAS, Hawaii has a shortage of mental health professionals and should actively consider novel, innovative, and safe treatment options to address the pressing need for appropriate mental health care; now, therefore, BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2023, the House of Representatives concurring, that the Department of Health is requested to establish a Therapeutic Psilocybin Working Group; and BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group is requested to examine: (1) Federal, state, and county laws, regulations, administrative rules, and procedures regarding the therapeutic use of psilocybin; (2) Medical, psychological, and scientific studies, research, and other information relating to the efficacy and safety of psilocybin or psilocybin-based products in treating mental health disorders, including post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress; and (3) Existing laws, requirements, and guidelines in jurisdictions in which psilocybin or psilocybin-based products are legally used to treat mental health conditions; and BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group is requested to determine and develop a long-term strategic plan to ensure the safe availability and accessibility of affordable, therapeutic psilocybin or psilocybin-based products for adults twenty-one years of age or older; and BE IT FURTHER RESOLVED that the following individuals, or their respective designees, are requested to serve as members of the Therapeutic Psilocybin Working Group: (1) The Director of Health, who shall serve as chairperson of the Working Group; (2) The Attorney General; (3) The Dean of the John A. Burns School of Medicine at the University of Hawaii at Manoa; (4) The chairperson of the Senate standing committees with primary jurisdiction over health and Judiciary subject matters; (5) The chairperson of the House of Representatives standing committees with primary jurisdiction over health and Judiciary subject matters; (6) The Chairperson of the Hawaii State Council on Mental Health; (7) A physician duly licensed pursuant to chapter 453, Hawaii Revised Statutes, or an advanced practice registered nurse who is authorized to prescribe psychotrophic medication and is duly licensed pursuant to chapter 457, Hawaii Revised Statutes, as invited by the chairperson of the Working Group; and (8) A psychiatrist duly licensed pursuant to chapter 453, Hawaii Revised Statutes, as invited by the chairperson of the Working Group; and BE IT FURTHER RESOLVED that the chairperson of the Therapeutic Psilocybin Working Group may invite other interested parties with relevant experience and expertise to join the Working Group; and BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group is requested to submit a report of its findings and recommendations, including the long-term strategic plan and any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2024; and BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group be dissolved on June 30, 2025; and BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Director of Health, Attorney General, Dean of the John A. Burns School of Medicine at the University of Hawaii at Manoa, and Chairperson of the Hawaii State Council on Mental Health. OFFERED BY: _____________________________ Report Title: Department of Health; Therapeutic Psilocybin Working Group; Report
46	46
47	47	WHEREAS, there is heightened awareness of the detrimental effects of untreated and maltreated mental health in the State's population; and
48	48
49	49
50	50
51	51	WHEREAS, with a shortage of mental health professionals and appropriate mental health care, the State must actively consider innovative and effective treatment options to address this pressing need; and
52	52
53	53
54	54
55	55	WHEREAS, psilocybin has been found to be very effective in treating a variety of mental health conditions, including but not limited to post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress; and
56	56
57	57
58	58
59	59	WHEREAS, the United States Food and Drug Administration has designated treatment that uses psilocybin in a therapeutic manner for treatment-resistant depression as a "breakthrough therapy"; and
60	60
61	61
62	62
63	63	WHEREAS, at least two states, Colorado and Oregon, have found that legalizing medicinal psilocybin is a valuable tool in dealing with various mental health conditions; and
64	64
65	65
66	66
67	67	WHEREAS, Hawaii has a shortage of mental health professionals and should actively consider novel, innovative, and safe treatment options to address the pressing need for appropriate mental health care; now, therefore,
68	68
69	69
70	70
71	71	BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2023, the House of Representatives concurring, that the Department of Health is requested to establish a Therapeutic Psilocybin Working Group; and
72	72
73	73
74	74
75	75	BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group is requested to examine:
76	76
77	77
78	78
79	79	(1) Federal, state, and county laws, regulations, administrative rules, and procedures regarding the therapeutic use of psilocybin;
80	80
81	81
82	82
83	83	(2) Medical, psychological, and scientific studies, research, and other information relating to the efficacy and safety of psilocybin or psilocybin-based products in treating mental health disorders, including post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress; and
84	84
85	85
86	86
87	87	(3) Existing laws, requirements, and guidelines in jurisdictions in which psilocybin or psilocybin-based products are legally used to treat mental health conditions; and
88	88
89	89
90	90
91	91	BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group is requested to determine and develop a long-term strategic plan to ensure the safe availability and accessibility of affordable, therapeutic psilocybin or psilocybin-based products for adults twenty-one years of age or older; and
92	92
93	93
94	94
95	95	BE IT FURTHER RESOLVED that the following individuals, or their respective designees, are requested to serve as members of the Therapeutic Psilocybin Working Group:
96	96
97	97
98	98
99	99	(1) The Director of Health, who shall serve as chairperson of the Working Group;
100	100
101	101
102	102
103	103	(2) The Attorney General;
104	104
105	105
106	106
107	107	(3) The Dean of the John A. Burns School of Medicine at the University of Hawaii at Manoa;
108	108
109	109
110	110
111	111	(4) The chairperson of the Senate standing committees with primary jurisdiction over health and Judiciary subject matters;
112	112
113	113
114	114
115	115	(5) The chairperson of the House of Representatives standing committees with primary jurisdiction over health and Judiciary subject matters;
116	116
117	117
118	118
119	119	(6) The Chairperson of the Hawaii State Council on Mental Health;
120	120
121	121
122	122
123	123	(7) A physician duly licensed pursuant to chapter 453, Hawaii Revised Statutes, or an advanced practice registered nurse who is authorized to prescribe psychotrophic medication and is duly licensed pursuant to chapter 457, Hawaii Revised Statutes, as invited by the chairperson of the Working Group; and
124	124
125	125
126	126
127	127	(8) A psychiatrist duly licensed pursuant to chapter 453, Hawaii Revised Statutes, as invited by the chairperson of the Working Group; and
128	128
129	129
130	130
131	131	BE IT FURTHER RESOLVED that the chairperson of the Therapeutic Psilocybin Working Group may invite other interested parties with relevant experience and expertise to join the Working Group; and
132	132
133	133
134	134
135	135	BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group is requested to submit a report of its findings and recommendations, including the long-term strategic plan and any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2024; and
136	136
137	137
138	138
139	139	BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group be dissolved on June 30, 2025; and
140	140
141	141
142	142
143	143	BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Director of Health, Attorney General, Dean of the John A. Burns School of Medicine at the University of Hawaii at Manoa, and Chairperson of the Hawaii State Council on Mental Health.
144	144
145	145
146	146
147	147
148	148
149	149
150	150
151	151	OFFERED BY: _____________________________
152	152
153	153
154	154
155	155	OFFERED BY:
156	156
157	157	_____________________________
158	158
159	159
160	160
161	161
162	162
163	163	Report Title:
164	164
165	165	Department of Health; Therapeutic Psilocybin Working Group; Report